{"id":3188,"date":"2018-04-25T05:48:31","date_gmt":"2018-04-25T09:48:31","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/"},"modified":"2026-09-24T00:09:49","modified_gmt":"2026-09-24T04:09:49","slug":"gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/","title":{"rendered":"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 25 avril 2018, 7h30 CET<\/strong> \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 mars 2018 et fait un point sur GS010.<strong>\u00a0<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Point sur GS010 dans la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le 3 avril 2018, GenSight Biologics a annonc\u00e9 les r\u00e9sultats pr\u00e9liminaires de l&rsquo;essai clinique de phase III REVERSE sur GS010 chez des patients atteints de Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL). A 48 semaines, l\u2019\u00e9tude a d\u00e9montr\u00e9 une am\u00e9lioration cliniquement significative de +11 lettres ETDRS dans les yeux trait\u00e9s avec GS010 et une am\u00e9lioration similaire dans les yeux controlat\u00e9raux non trait\u00e9s (trait\u00e9s par injection simul\u00e9e ou <em>sham<\/em>) chez les 37 sujets inclus, sugg\u00e9rant un effet bilat\u00e9ral inattendu du traitement. Egalement, les mesures SD-OCT ont d\u00e9montr\u00e9 de fa\u00e7on statistiquement significative la relative pr\u00e9servation du volume des cellules ganglionnaires de la r\u00e9tine et de l\u2019\u00e9paisseur de la couche de fibres nerveuses dans les yeux trait\u00e9s, alors que les yeux non trait\u00e9s continuaient \u00e0 se d\u00e9grader.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Suite \u00e0 ces r\u00e9sultats pr\u00e9liminaires, GenSight Biologics \u00e9value les donn\u00e9es compl\u00e8tes de l\u2019\u00e9tude, et conduit un certain nombre d\u2019analyses <em>post hoc<\/em>, afin de mieux comprendre l\u2019effet du traitement et les profils de r\u00e9pondeurs. La Soci\u00e9t\u00e9 collabore \u00e9galement avec les leaders d\u2019opinion (KOLs), les investigateurs et experts cliniques pour \u00e9valuer si les \u00e9tudes de Phase III en cours RESCUE et REFLECT pourraient \u00eatre optimis\u00e9es \u00e0 la lumi\u00e8re des enseignements de REVERSE.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GenSight Biologics devrait terminer ces analyses et discussions d\u2019ici la fin du mois de mai, et tiendra un <strong><em>R&amp;D Day<\/em><\/strong><strong> \u00e0 New York le 5 juin 2018<\/strong> (<em>d\u00e9tails \u00e0 confirmer<\/em>). Au cours de cet \u00e9v\u00e8nement, le Management et des KOLs de renomm\u00e9e internationale pr\u00e9senteront des donn\u00e9es suppl\u00e9mentaires de REVERSE, discuteront les conclusions et les attentes des communaut\u00e9s m\u00e9dicale et de patients, et feront un point sur les strat\u00e9gies clinique et r\u00e9glementaire de GS010. L\u2019\u00e9v\u00e8nement sera retransmis en webcast.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Situation nette de tr\u00e9sorerie<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La situation nette de tr\u00e9sorerie de GenSight Biologics s\u2019\u00e9tablissait \u00e0 49,2 millions d\u2019euros au 31 mars 2018, compar\u00e9e \u00e0 55,4 millions d\u2019euros au 31 d\u00e9cembre 2017.<strong>\u00a0<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre d\u2019actions composant le capital social<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Au 31 mars 2018, le nombre d\u2019actions composant le capital social de GenSight Biologics \u00e9tait de 24\u00a0234\u00a0223 actions ordinaires.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GenSight Biologics publiera ses r\u00e9sultats financiers semestriels 2018 le 25 juillet 2018.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (<em>Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, GS010, est en Phase III pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare qui conduit \u00e0 une perte irr\u00e9versible de la vue chez les adolescents et les jeunes adultes. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 25 avril 2018, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3188","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 25 avril 2018, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2018-04-25T09:48:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:09:49+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/04\\\/25\\\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/04\\\/25\\\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010\",\"datePublished\":\"2018-04-25T09:48:31+00:00\",\"dateModified\":\"2026-09-24T04:09:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/04\\\/25\\\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\\\/\"},\"wordCount\":656,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/04\\\/25\\\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/04\\\/25\\\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\\\/\",\"name\":\"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2018-04-25T09:48:31+00:00\",\"dateModified\":\"2026-09-24T04:09:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/04\\\/25\\\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/04\\\/25\\\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2018\\\/04\\\/25\\\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010 - GenSight Biologics","og_description":"Paris, France, le 25 avril 2018, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, publie aujourd\u2019hui sa situation nette de tr\u00e9sorerie au 31 [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/","og_site_name":"GenSight Biologics","article_published_time":"2018-04-25T09:48:31+00:00","article_modified_time":"2026-09-24T04:09:49+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010","datePublished":"2018-04-25T09:48:31+00:00","dateModified":"2026-09-24T04:09:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/"},"wordCount":656,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/","name":"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2018-04-25T09:48:31+00:00","dateModified":"2026-09-24T04:09:49+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2018\/04\/25\/gensight-biologics-publie-e49-millions-de-tresorerie-nette-au-31-mars-2018-et-fait-un-point-sur-gs010\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics publie \u20ac49 millions de tr\u00e9sorerie nette au 31 mars 2018 et fait un point sur GS010"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3188"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3188\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3188"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3188"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3188"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3188"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}